

Motegrity[®] (prucalopride) – First-time generic

- On January 2, 2025, [ANI Pharmaceuticals launched](#) an [AB-rated](#) generic version of Takeda's [Motegrity \(prucalopride\)](#) tablets.
 - ANI was granted a Competitive Therapy Designation, with 180-days of exclusivity.
- Motegrity is approved for the treatment of chronic idiopathic constipation in adults.
- According to IQVIA, Motegrity had \$168 million in annual U.S. sales through October 2024.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.